9. Vadadustat will be marketed by MTPC in Japan under the trade name VAFSEO™. Akebia’s privacy procedures do not apply to the owners of a non-Akebia website. Iron Deficiency Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Iron helps make red blood cells. Drüeke TB, Locatelli F, Clyne N, et al; CREATE Investigators.
4. Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT).
Hypoxia-inducible factors and the response to hypoxic stress. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. When body does not have enough iron, it will make fewer red blood cells or red blood cells that are too small. Hypoxia-inducible factors in the kidney. Amicus Therapeutics informs you that our website uses its own and third party cookies to improve our services and collect statistical information about your browsing. Symptoms include feeling grumpy, headaches and problems concentrating or thinking. Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT). Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Iron Deficiency Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Review the pipeline and the status of clinical studies investigating APL-2 (pegcetacoplan) & APL-9 as a treatment for autoimmune and inflammatory diseases, including geographic atrophy (GA), paroxysmal nocturnal hemoglobinuria (PNH), cold agglutinin disease (CAD), warm antibody autoimmune hemolytic anemia (wAIHA), and complement dependent nephropathies (CDN) The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Iron Deficiency Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Iron Deficiency Anemia and features dormant and discontinued projects. 7. Available at: https://clinicaltrials.gov/ct2/show/NCT02892149. Beginning in the mid-2000s, however, ESA use in CKD became more conservative amid evidence showing that use was associated with elevated risk of cardiovascular events, stroke, and death. Haase VH. Send. Akebia’s privacy procedures do not apply to the owners of a non-Akebia website. [email protected] From 2000 to 2006, Dr. Burke served as Senior Vice President of Medical and Regulatory Affairs at Genzyme Corporation, where he worked from 2001 to 2006. … KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Portoles J, Gorriz JL, Rubio E, et al. For more information about this drug pipelines report visit The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. All other readers will be directed to the abstract and would need to subscribe. It can commonly occur in people with chronic kidney disease (CKD) because their kidneys do not produce enough erythropoietin (EPO), which is a hormone released into the blood to help regulate the production of red blood cells. U.S. National Library of Medicine. Majmundar AJ, Wong WJ, Simon MC. Based on Nobel Prize-winning science, vadadustat is an oral HIF-PHI in clinical development for the treatment of anemia due to CKD in dialysis dependent and non-dialysis dependent adult patients. TRACK . Our team works to address complications of kidney disease. 10. Cancel. The Pharmaceutical and Healthcare latest pipeline guide Iron Deficiency Anemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Iron Deficiency Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. 52 Number of Organizations • $1.1B Total Funding Amount • 101 Number of Investors. Anemia in Chronic Kidney Disease.